ClinicalTrials.gg
RecruitingNCT05975749Updated Mar 12, 2024

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

A Phase 2 interventional study of Serplulimab and Trastuzuma in Gastric Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2023, registered Jul 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing serplulimab in Stomach Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. serplulimab · Stomach Neoplasms.

Planned enrollment
4th of 14
114 · median 59
Started
2023
with 1 other
Phase 2
13 of 14
8 open now
Primary completion
2026-01
later than 1 of 10 live
Registered
6th of 14
by date
Lead sponsor
2 of 14
Fudan University

Among the 14 studies testing serplulimab in Stomach Neoplasms, this one is the 4th largest by planned enrollment, is one of 2 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 6th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing serplulimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Gastric Cancer
  • Adjuvant treatment
  • Trastuzuma
  • Serplulimab
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Lower age limit of research subjects 20 years old and upper age limit of 80 years old.
  2. Be proven to be primary adenocarcinoma of gastric cancer and staged II-III by pathological evidences
  3. R0 gastrectomy with D2 lymphadenectomy
  4. Her2+ diagnosed by Immunohistochemistry or FISH
  5. (ECOG score standard) performance status of 0 or 1 and expected to survive more than 6 months
  6. No , including normal peripheral blood routine, liver and kidney function and (WBC≥3.5 x 109 /L, NEU≥1.2 x 109 /L,≥90 x 109 /L and HGB≥80g/L).

Exclusion criteria

Exclusion Criteria:

  1. Patients with stage I and IV.
  2. Unavailable for R0 resection and D2 lymph node dissection.
  3. Multiple primary tumors
  4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.
  5. History of chemotherapy, radiotherapy, immunotherapy or target therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Adjuvant Treatment of Serplulimab and Trastuzuma and Chemotherapy

    Drug: Serplulimab · Drug: Trastuzuma · Drug: Chemotherapy

  • Active comparator
    Adjuvant Chemotherapy only

    Drug: Chemotherapy

Interventions

  • Serplulimab: 4.5mg/Kg on day 1

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzuma: 8mg/Kg ( the first cycle),6mg/Kg (the rest of cycles) on day 1

  • DrugChemotherapy

    Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    DFS

    Time frame: 3-year

Secondary outcomes

  1. Overall survival

    OS

    Time frame: 3-year

  2. Side effects

    Complications such as Nausea, vomiting, myelosuppression and Liver or kidney function disorder

    Time frame: 12 months]

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 36 months after the start.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 36 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 4, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2029
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05975749
Lead sponsor
Fudan University
Responsible party
Dazhi Xu (Professor, Fudan University) — Principal investigator
First posted
Aug 4, 2023
Start date
Jan 1, 2023
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Mar 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Serplulimab · Trastuzumab

Start the discussion